**Name of Journal:** *World Journal of Gastroenterology*

**Manuscript NO:** 61426

**Manuscript Type:** ORIGINAL ARTICLE

***Basic Study***

**Circular RNA circVAPA promotes chemotherapy drug resistance in gastric cancer progression by regulating miR-125b-5p/STAT3 axis**

Deng P *et al*. CircVAPA promotes chemotherapy drug resistance

Peng Deng, Ming Sun, Wen-Yan Zhao, Bin Hou, Kai Li, Tao Zhang, Feng Gu

**Peng Deng, Bin Hou, Kai Li,** Department ofSurgical Oncology and General Surgery, Key Laboratory of Precision Diagnosis and Treatment of Gastrointestinal Tumors, Ministry of Education, The First Affiliated Hospital of China Medical University, Shenyang 110001, Liaoning Province, China

**Ming Sun,** Department of Urology, Shengjing Hospital of China Medical University, Shenyang 110004, Liaoning Province, China

**Wen-Yan Zhao,** Department of General Surgery, Shengjing Hospital of China Medical University, Shenyang 110004, Liaoning Province, China

**Tao Zhang,** Department of Stem Cells and Regenerative Medicine, China Medical University, Shenyang 110122, Liaoning Province, China

**Feng Gu,** Department of Ophthalmology, The First Affiliated Hospital of China Medical University, Shenyang 110001, Liaoning Province, China

**Author contributions:** Deng P and Sun M performed the majority of experiments and analyzed the data; Zhao WY performed the molecular investigations; Hou B and Gu F designed and coordinated the research; Li K and Zhang T wrote the paper.

**Corresponding author: Feng Gu, PhD, Chief Physician,** Department of Ophthalmology, The First Affiliated Hospital of China Medical University, No. 155 Nanjing North street, Heping District, Shenyang 110001, Liaoning Province, China. fenggu78186069@163.com

**Received:** December 6, 2020

**Revised:** December 21, 2020

**Accepted:** January 7, 2021

**Published online:**

**Abstract**

BACKGROUND

Gastric cancer (GC) is a prevalent malignancy, leading to a high incidence of cancer-associated death. Cisplatin (DDP)-based chemotherapy is the principal therapy for clinical GC treatment, but DDP resistance is a severe clinical challenge and the mechanism remains poorly understood. Circular RNAs (circRNAs) have been identified to play crucial roles in modulating the chemoresistance of gastric cancer cells.

AIM

To explore the effect of circVAPA on chemotherapy resistance during GC progression.

METHODS

The effect of circVAPA on GC progression and chemotherapy resistance was analyzed by MTT assay, colony formation assay, Transwell assay, wound healing assay, and flow cytometry analysis in GC cells and DDP resistant GC cell lines, and tumorigenicity analysis in nude mice *in vivo*. The mechanism was investigated by luciferase reporter assay, quantitative real-time PCR, and Western blot analysis.

RESULTS

CircVAPA expression was up-regulated in clinical GC tissues compared with normal samples. CircVAPA depletion inhibited proliferation, migration, and invasion and increased apoptosis of GC cells. The expression of circVAPA, STAT3, and STAT3 downstream genes was elevated in DDP resistant SGC7901/DDP cell lines. CircVAPA knockdown attenuated the DDP resistance of GC cells. Mechanically, circVAPA was able to sponge miR-125b-5p, and miR-125b-5p could target STAT3 in the GC cells. MiR-125b-5p inhibitor reversed circVAPA depletion-enhanced inhibitory effect of DDP on GC cells, and STAT3 knockdown blocked circVAPA overexpression-induced proliferation of DDP-treated SGC7901/DDP cells. The depletion of STAT3 and miR-125b-5p inhibitor reversed circVAPA depletion-induced GC cell apoptosis. Functionally, circVAPA contributed to the tumor growth of SGC7901/DDP cells *in vivo*.

CONCLUSION

CircVAPA promotes chemotherapy resistance and malignant progression in GC by miR-125b-5p/STAT3 signaling. Our findings present novel insights into the mechanism by which circVAPA regulates chemotherapy resistance of GC cells. CircVAPA and miR-125b-5p may be considered as the potential targets for GC therapy.

**Key Words:** Gastric cancer; Progression; Chemoresistance; CircVAPA; miR-125b-5p; STAT3

Deng P, Sun M, Zhao WY, Hou B, Li K, Zhang T, Gu F. Circular RNA circVAPA promotes chemotherapy drug resistance in gastric cancer progression by regulating miR-125b-5p/STAT3 axis. *World J Gastroenterol* 2021; In press

**Core Tip:** We concluded that circVAPA contributed to chemotherapy resistance and malignant progression in gastric cancer (GC) by miR-125b-5p/STAT3 signaling. Our findings present novel insights into the mechanism that circVAPA regulates chemotherapy resistance of GC cells. CircVAPA and miR-125b-5p may be considered as potential targets for GC therapy.

**INTRODUCTION**

Gastric cancer (GC) is a prevalent malignancy and the second cause of tumor-associated mortality in the world[1]. Chemotherapy is a favored strategy toward advanced-stage GC cases, in which oxaliplatin, cisplatin (DDP), and 5-FU are usually admitted as first-line therapies[2-4]. Although the improved chemotherapy effectiveness, the GC patients' survival is still unsatisfactory, and chemotherapy always attains a low response rate[5,6]. Whether intrinsic or acquired, chemoresistance is a significant challenge for GC treatment efficiency in the clinic[7]. The mechanism for GC chemotherapy resistance development is not well-understood, in which microenvironmental and genetic contributors are able to result in chemoresistance[8]. Hence, understanding the molecular mechanism of chemotherapy resistance in GC is urgently needed.

Circular RNAs (circRNAs), as an emerging class of non-coding RNAs, present various functions in the regulation of gene expression at the post-transcriptional and transcriptional levels[9]. It has been identified that circRNAs are able to serve as the competitive endogenous sponge for microRNAs (miRNAs) and thereby inhibit miRNAs, providing a new manner for modulating miRNAs and indicating a promising mechanism of circRNA function[10,11]. Meanwhile, previous studies have reported that circVAPA is elevated in tumors and contributes to cancer progression, such as liver cancer and breast cancer[12,13]. MiRNAs are short non-coding RNAs with a length of about 22nt and can target various genes by pairing with the mRNAs at the post-transcriptional level[14,15]. MiR-125b-5p is a well-investigated tumor suppressor in multiple cancer models, including bladder cancer, laryngeal squamous cell carcinoma, and colon cancer[16-18]. Furthermore, it has been well-identified that circRNAs and miRNAs are involved in the chemotherapy resistance in GC[8,19-21]. However, the role of circVAPA and miR-125b-5p in modulating chemotherapy resistance of GC cells is still unreported.

It has been recognized that STAT3 serves as a critical regulator in tumorigenesis[22]. As an important transcriptional factor, STAT3 is able to mediate multiple gene expression in modulating cell survival response to different stimulations[23]. Furthermore, STAT3 remarkably promotes chemoresistance as a crucial indicator in GC cells by various mechanisms, such as increasing the expression of vacuolar ATPase pump and oncogenes as well as the apoptotic factors[24]. Nevertheless, the impact of circVAPA and miR-125b-5p on STAT3 in the regulation of GC cells chemotherapy resistance is still unclear.

In this study, we were interested in the function of circVAPA in the progression of chemotherapy resistance of GC cells. We found an unreported role of circVAPA in enhancing chemotherapy resistance and promoting the malignant progression of GC by modulating miR-125b-5p/STAT3 signaling.

**MATERIALS AND METHODS**

***GC clinical samples***

The clinical GC tissue samples (*n* = 50) and adjacent normal tissues (*n* = 50) were obtained from the First Affiliated hospital of China Medical University. The diagnosis of cases was performed by two clinicians based on histopathological analysis. The samples were collected and immediately stored at -80 °C followed by further analysis. The samples were written-approved by the patients. This study conformed to the experimental guidelines of the World Medical Association and the Ethics Committee of the First Affiliated hospital of China Medical University.

***Cell culture and treatment***

The SGC7901, HGC27, and SGC7901/DDP cell lines were maintained in the laboratory. The cells were incubated in an incubator at 5% CO2 and37 °C in the Dulbecco's modified Eagle’s medium (DMEM) medium (Hyclone, United States) with fetal bovine serum (10%, Hyclone, United States), streptomycin (0.1 mg/mL, Hyclone, United States), and penicillin (100 units/mL, Hyclone, United States). DDP was obtained from Sigma (United States). The circVAPA shRNA, pcDNA3.1-circVAPA, pcDNA3.1-STAT3, STAT3 siRNA, miR-125b-5p mimic, and miR-125b-5p inhibitor were purchased from GenePharma (China). The transfection in the cells was performed with Liposome 2000 (Invitrogen, United States).

***MTT assay***

The cell viability was assessed by MTT assays at various time points in 6-well dishes. Briefly, the MTT solution (Solarbio, China) was added into the cells and cultured at the condition of 5% CO2 and 37 °C for 4 h. After that, dimethyl sulfoxide (DMSO; 100 μL, 10 min; Sigma, United States) was used to terminate the reaction. The cell viability was analyzed at the absorbance of 490 nm by applying a microplate reader (Thermo, United States).

***Colony formation assay***

About 1 × 103 cells were plated in 6-well dishes and cultured in DMEM at the condition of 5% CO2 and 37 °C. After 2 wk, cells were washed with phosphate buffered saline (PBS) buffer, made in methanol about 30 min, and dyed with 1% crystal violet dye solution, after which the number of colonies was calculated.

***Transwell assay***

Transwell assays were performed to analyze cell invasion and migration using a Transwell plate (Corning, United States) according to the manufacturer's instructions. Briefly, the upper chamber was plated with around 1 × 105 cells. The cells were then fixed with 4% paraformaldehyde and dyed with crystal violet. The invaded and migrated cells were recorded and calculated.

***Wound healing assay***

Cells were plated in a 24-well plate at 3 × 105/well and cultured overnight to reach full confluence as a monolayer. A 20 μL pipette tip was applied to slowly cut a straight line across the well. Then the well was washed with PBS three times and changed with the serum-free medium and continued to culture. The wound healing percentage was calculated.

***Analysis of cell apoptosis***

Cell apoptosis was measured by applying the Annexin-V-FITC apoptosis kit (BD, United States) based on flow cytometry analysis using a FACSCalibur flow cytometer, followed by the quantification analysis using FlowJo software.

***Luciferase reporter gene assay***

SGC7901 and HGC27 cells were plated in 24-well dishes followed by treatment with miR-125b-5p mimic. After 48 h of the treatment, the luciferase activities were analyzed by utilizing the luciferase reporter assays (Promega, United States). The relative luciferase activities were analyzed by the Renilla luciferase activities.

***Quantitative real-time PCR***

RNA isolation was performed by applying TRIzol reagent (Solarbio, China) and the first-strand cDNA was synthesized (Solarbio, China). Quantitative real-timePCR was carried out by applying SYBR-Green (Takara, China). The primer sequences are as follows: circVAPA forward: 5′-TGGATTCCAAATTGAGATGCGTATT-3′, reverse: 5′-CACTTTTCTATCCGATGGATTTCGC-3′; miR-125b-5p forward: 5′-TCCCTGAGACCCTAACTTGTGA-3′, reverse: 5′- AGTCTCAGGGTCCGAGGTATTC-3′; STAT3 forward: 5′-CTGGCCTTTGGTGTTGAAAT-3′, reverse: 5′-AAGGCACCCACAGAAACAAC-3′; GAPDH forward: 5′-AAGAAGGTGGTGAAGCAGGC-3′, reverse: 5′-TCCACCACCCAGTTGCTGTA-3′.

***Western blot analysis***

Total proteins were extracted from the cells using radioimmunoprecipitation assay buffer (CST, United States) and quantified using the BCA Protein Quantification Kit (Abbkine, United States). The proteins at the same concentration were subjected to sodium dodecyl sulfate- polyacrylam-ide gel electrophoresis and transferred to polyvinylidene fluoride membranes (Millipore, United States), followed by incubation with 5% milk and with the primary antibodies at 4 °C overnight. The corresponding second antibodies (BOSTER, China) were used for incubating the membranes for 1 h at room temperature, followed by visualization using a chemiluminescence detection kit (Beyyotime, China). The primary antibodies applied in this study comprised STAT3 (Abcam, United States), p-STAT3 (Abcam, United States), Survivin (Abcam, United States), Mcl-1 (Abcam, United States), Bcl-xl (Abcam, United States), and β-actin (Abcam, United States).

***Analysis of tumorigenicity in nude mice***

The tumor growth of GC cells *in vivo* was tested in nude Balb/c mice (4-week-old, male, *n* = 5). And about 1 × 107 SGC7901/DDP cells were subcutaneously injected in the mice. Five days after injection, we measured tumor growth every 5 d. We sacrificed the mice 30 d after injection, and tumors were scaled. Tumor volume (V) was observed by estimating the length (L) and width (W) with calipers and calculated as (L × W2) × 0.5. Animal care and method procedure were authorized by the Animal Ethics Committee of the First Affiliated hospital of China Medical University.

***Statistical analysis***

Data are presented as the mean ± SD, and statistical analyses were performed with GraphPad Prism 7. The unpaired Student’s *t*-test was applied for comparing the difference between two groups, and one-way ANOVA was applied for comparing among multiple groups. a*P* < 0.05 were considered statistically significant.

**RESULTS**

***CircVAPA enhances proliferation and represses apoptosis of GC cells***

To identify the clinical association of circVAPA with GC, we analyzed the expression of circVAPA in the clinical GC samples. Our data showed that circVAPA expression was elevated in the GC tissue samples (*n* = 50) relative to that in the adjacent normal tissues (*n* = 50), implying the potential correlation of circVAPA with GC (Figure 1A). The cell viability was reduced by the depletion of circVAPA in the SGC7901 and HGC27 cell lines (Figure 1B and C). Similarly, colony formation assays revealed that circVAPA shRNA treatment remarkably decreased the colony numbers of SGC7901 and HGC27 cells (Figure 1D and E). Furthermore, apoptosis of SGC7901 and HGC27 cells was induced by circVAPA knockdown (Figure 1F and G). These findings indicated that circVAPA is able to increase proliferation and attenuate apoptosis of GC cells

***CircVAPA promotes invasion and migration of GC cells***

Next, the function of circVAPA in modulating migration and invasion of GC cells was assessed. Transwell assays demonstrated that migration and invasion of SGC7901 and HGC27 cells were alleviated by circVAPA shRNA (Figure 2A and B). Besides, wound healing assays showed that circVAPA depletion remarkably increased wound proportion in SGC7901 and HGC27 cell lines (Figure 2C and D). These data indicated that circVAPA contributes to migration and invasion of GC cells.

***Elevation of circVAPA enhances chemotherapy drug resistance of GC cells***

Next, we were interested in the impact of circVAPA on the chemoresistance of GC cells. To this end, we first explored the expression of circVAPA in SGC7901 and DDP resistant SGC7901/DDP cell lines. Significantly, the expression of circVAPA was up-regulated in SGC7901/DDP cells compared with that in SGC7901 cells (Figure 3A). Meanwhile, STAT3 phosphorylation, STAT3 expression, and STAT3 downstream gene (including Survivin, Mcl-1, and Bcl-xl) expression were elevated in the SGC7901/DDP cells relative to those in SGC7901 cells (Figure 3A and B). Importantly, depletion of circVAPA remarkably reduced the IC50 value of DDP for the inhibition of SGC7901/DDP cells (Figure 3C). In addition, DDP was able to induce apoptosis of SGC7901/DDP cells, and circVAPA depletion notably reinforced this effect in the system (Figure 3D). Together, these findings suggested that circVAPA contributes to chemotherapy drug resistance of GC cells.

***CircVAPA is able to sponge miR-125b-5p in gastric cancer cells***

Next, we explored the mechanism of circVAPA-mediated GC progression and chemotherapy resistance. The bioinformatic analysis revealed the potential interaction of circVAPA and miR-125b-5p (Figure 4A). The SGC7901 and HGC27 cells were treated with miR-125b-5p mimic and the enhancement of miR-125b-5p was confirmed in the cells (Figure 4B). Treatment with miR-125b-5p mimic was able to decrease luciferase activities of wild type circVAPA, but not circVAPA mutant in the cells (Figure 4C and D). Moreover, the expression of miR-125b-5p was up-regulated by circVAPA shRNA in the SGC7901 and HGC27 cells. These findings indicated that circVAPA spongs miR-125b-5p in the GC cells (Figure 4E and F).

***MiR-125b-5p targets STAT3 in GC cells***

Furthermore, we identified the binding site of miR-125b-5p within the 3’ untranslated region of the *STAT3* gene through bioinformatic analysis (Figure 5A). Treatment with miR-125b-5p mimic repressed luciferase activities of STAT3, but not STAT3 mutant in the SGC7901 and HGC27 cells (Figure 5B). Consistently, the mRNA and protein levels of STAT3 were inhibited by the miR-125b-5p mimic in the cells (Figure 5C and D). Moreover, circVAPA knockdown down-regulated STAT3 in the SGC7901 and HGC27 cells, while miR-125b-5p inhibitor was able to reverse this effect in the cells (Figure 5E).

***CircVAPA promotes chemotherapy drug resistance of GC cells by modulating miR-125b-5p/STAT3 axis***

We then investigated whether circVAPA mediates chemotherapy drug resistance of GC cells by modulating the miR-125b-5p/STAT3 axis. Significantly, depletion of circVAPA enhanced the inhibitory effect of DDP on SGC7901 and HGC27 cell viability, while miR-125b-5p inhibitor rescued this phenotype in the cells (Figure 6A and B). In addition, overexpression of circVAPA promoted the proliferation of DDP-treated SGC7901/DDP cells, while STAT3 siRNA could reduce this effect in the system (Figure 6C). Meanwhile, circVAPA knockdown reinforced DDP-induced apoptosis of SGC7901 and HGC27 cells, whereas miR-125b-5p inhibitor or STAT3 overexpression could reverse this effect (Figure 6D). These results suggested that circVAPA promotes chemotherapy resistance of GC cells by modulating the miR-125b-5p/STAT3 axis (Figure 6E).

***CircVAPA promotes the tumor growth of chemoresistant gastric cancer cell in vivo***

Next, the circVAPA function in GC cell growthwas analyzed by tumorigenicity analysis *in vivo*. The tumor growth of GC cells was inhibited by circVAPA knockdown, as presented by the decreased tumor size, tumor volume, and tumor weight in the nude mice (Figure 7A-C). Meanwhile, we validated that miR-125b-5p expression was up-regulated while STAT3 expression was down-regulated by circVAPA depletion in the tumor tissues (Figure 7D and E). Together, these data indicated that circVAPA contributes to the tumor growth of chemoresistant GC cells *in vivo.*

**DISCUSSION**

The chemotherapy resistance in GC patients is a severe clinical challenge, and the molecular mechanism is still poorly understood[7]. CircRNAs have been identified to participate in the modulation of GC progression[25]. Nevertheless, the specific functions of circVAPA in the modulation of GC development remain obscure. In the present study, we uncovered that circVAPA contributed to chemotherapy resistance and promoted the malignant progression in GC by modulating miR-125b-5p/ STAT3 signaling.

As a critical cancer regulator, several circRNAs have been identified in the modulation of chemotherapy resistance during GC progression. It has been reported that circ-PVT1 promotes paclitaxel resistance by regulating miR-124-3p/ZEB1 in GC cells[26]. Circ0026359 increases the DDP resistance of GC cells by modulating the miR-1200/POLD4 axis[27]. CircAKT3 promotes DDP resistance by up-regulating PIK3R1 through targeting miR-198 in GC cells[28]. CircFN1 contributes to DDP resistance of GC cells by targeting miR-182-5p[29]. CircMCTP2 attenuates DDP resistance by miR-99a-5p/MTMR3 signaling in GC cells[30]. Moreover, circVAPA presents oncogenic properties in cancers, including liver cancer and colorectal cancer[13,31]. In this study, circVAPA expression was elevated in the clinical GC samples. CircVAPA depletion inhibited proliferation, migration, and invasion, and increased apoptosis of GC cells. CircVAPA knockdown reduced tumor growth of GC cells *in vivo.* CircVAPA contributed to chemotherapy drug resistance of GC cells. These findings present a novel function of circVAPA in modulating chemotherapy drug resistance and malignant progression of GC cells, indicating valuable evidence of circRNA function in GC development.

MiRNAs are the essential contributor for regulating chemotherapy drug resistance of GC cells. It has been reported that miR-625 inhibits chemotherapy resistance by regulating ALDH1A1 in GC cells[32]. MiR-21-5p regulates doxorubicin resistance of GC cells *via* modulating TIMP3 and PTEN expression[33]. MiR-187 affects DDP resistance by targeting transforming growth factor-β signaling in GC cells[34]. Moreover, constitutive activation of STAT3 contributes to chemotherapy resistance of GC cells[35]. STAT3 signaling is involved in fibroblasts-mediated chemoresistance of GC cells[36]. Suppression of STAT3 inhibits drug resistance of GC cells to chemotherapeutic drugs[37]. In the mechanistic study, we found that circVAPA sponged miR-125b-5p and miR-125b-5p targeted STAT3 in the GC cells. MiR-125b-5p inhibitor rescued circVAPA depletion-enhanced inhibitory effect of DDP on GC cells, and STAT3 knockdown blocked circVAPA overexpression-induced proliferation of DDP-treated SGC7901/DDP cells. Depletion of STAT3 and miR-125b-5p inhibitor reversed circVAPA depletion-induced GC cell apoptosis. These data demonstrate an unreported regulation axis associated circVAPA with STAT3 and miR-125b-5p, revealing a new mechanism involving the circVAPA/miR-125b-5p/STAT3 axis in GC development.

**CONCLUSION**

CircVAPA promotes chemotherapy resistance and the malignant progression in GC by modulating miR-125b-5p/STAT3 signaling. Our findings present novel insights into the mechanism by which circVAPA regulates chemotherapy resistance of GC cells. CircVAPA and miR-125b-5p may be considered as potential targets for GC therapy.

**ARTICLE HIGHLIGHTS**

***Research background***

Gastric cancer (GC) is a common malignant tumor and causes a high incidence of cancer-associated death. Cisplatin (DDP)-based chemotherapy is the main therapy for clinical GC treatment, but the mechanism of chemotherapy resistance is still poorly understood, which is a severe clinical challenge. CircRNAs have been identified to play a vital role in regulating the chemoresistance of gastric cancer cells. The development process of GC chemotherapy resistance is not well-understood. In addition, it is well known that circRNAs and miRNAs are involved in chemotherapy resistance of GC cells. However, the role of circVAPA and miR-125b-5p in regulating the chemotherapy resistance of GC cells has not been reported yet.

***Research motivation***

To investigate the impact of circVAPA on chemotherapy resistance during the progression of GC.

***Research objectives***

We collected the clinical GC tissue samples (*n* = 50) and the adjacent normal tissues (*n* = 50) and analyzed the effect of circVAPA on GC progression and chemotherapy resistance.

***Research methods***

The role of circVAPA in chemotherapy resistance and GC progression was analyzed by transwell assay, MTT assay, colony formation assay, healing assay, and wound flow cytometry analysis in GC cells and DDP resistant GC cell lines, and *in vivo* tumorigenicity analysis in nude mice. The mechanism was investigated by quantitative real-time PCR, luciferase reporter assay, and Western blot analysis.

***Research results***

CircVAPA depletion inhibited proliferation, migration, and invasion and increased apoptosis of GC cells. CircVAPA knockdown reduced tumor growth of GC cells *in vivo*. CircVAPA promoted the chemotherapy resistance of GC cells. We found that circVAPA targeted miR-125b-5p and miR-125b-5p to STAT3 in GC cells. MiR-125b-5p inhibitor rescued the depletion of circVAPA and enhanced the inhibitory effect of DDP on GC cells, while STAT3 knockdown prevented the proliferation of DDP-treated SGC7901/DDP cells induced by circVAPA overexpression. Depletion of STAT3 and miR-125b-5p inhibitor reversed circVAPA depletion-induced GC cell apoptosis.

***Research conclusions***

CircVAPA promotes chemotherapy resistance and the malignant progression of GC cells by modulating miR-125b-5p/STAT3 signaling. CircVAPA and miR-125b-5p may be considered as potential targets for GC therapy.

***Research perspectives***

CircRNA circVAPA promotes chemotherapy drug resistance in the progression of gastric cancer by regulating the miR-125b-5p/STAT3 axis.

**REFERENCES**

1 **Marin JJ**, Al-Abdulla R, Lozano E, Briz O, Bujanda L, Banales JM, Macias RI. Mechanisms of Resistance to Chemotherapy in Gastric Cancer. *Anticancer Agents Med Chem* 2016; **16**: 318-334 [PMID: 26234359 DOI: 10.2174/1871520615666150803125121]

2 **Ham IH**, Oh HJ, Jin H, Bae CA, Jeon SM, Choi KS, Son SY, Han SU, Brekken RA, Lee D, Hur H. Targeting interleukin-6 as a strategy to overcome stroma-induced resistance to chemotherapy in gastric cancer. *Mol Cancer* 2019; **18**: 68 [PMID: 30927911 DOI: 10.1186/s12943-019-0972-8]

3 **Zhai J**, Shen J, Xie G, Wu J, He M, Gao L, Zhang Y, Yao X, Shen L. Cancer-associated fibroblasts-derived IL-8 mediates resistance to cisplatin in human gastric cancer. *Cancer Lett* 2019; **454**: 37-43 [PMID: 30978440 DOI: 10.1016/j.canlet.2019.04.002]

4 **Zheng P**, Chen L, Yuan X, Luo Q, Liu Y, Xie G, Ma Y, Shen L. Exosomal transfer of tumor-associated macrophage-derived miR-21 confers cisplatin resistance in gastric cancer cells. *J Exp Clin Cancer Res* 2017; **36**: 53 [PMID: 28407783 DOI: 10.1186/s13046-017-0528-y]

5 **Guo W**, Deng L, Chen Z, Chen Z, Yu J, Liu H, Li T, Lin T, Chen H, Zhao M, Zhang L, Li G, Hu Y. Vitamin B12-conjugated sericin micelles for targeting CD320-overexpressed gastric cancer and reversing drug resistance. *Nanomedicine (Lond)* 2019; **14**: 353-370 [PMID: 30328369 DOI: 10.2217/nnm-2018-0321]

6 **Xu Z**, Chen L, Xiao Z, Zhu Y, Jiang H, Jin Y, Gu C, Wu Y, Wang L, Zhang W, Zuo J, Zhou D, Luan J, Shen J. Potentiation of the anticancer effect of doxorubicinin drug-resistant gastric cancer cells by tanshinone IIA. *Phytomedicine* 2018; **51**: 58-67 [PMID: 30466628 DOI: 10.1016/j.phymed.2018.05.012]

7 **Min A**, Kim JE, Kim YJ, Lim JM, Kim S, Kim JW, Lee KH, Kim TY, Oh DY, Bang YJ, Im SA. Cyclin E overexpression confers resistance to the CDK4/6 specific inhibitor palbociclib in gastric cancer cells. *Cancer Lett* 2018; **430**: 123-132 [PMID: 29729292 DOI: 10.1016/j.canlet.2018.04.037]

8 **Yuan L**, Xu ZY, Ruan SM, Mo S, Qin JJ, Cheng XD. Long non-coding RNAs towards precision medicine in gastric cancer: early diagnosis, treatment, and drug resistance. *Mol Cancer* 2020; **19**: 96 [PMID: 32460771 DOI: 10.1186/s12943-020-01219-0]

9 **Kristensen LS**, Hansen TB, Venø MT, Kjems J. Circular RNAs in cancer: opportunities and challenges in the field. *Oncogene* 2018; **37**: 555-565 [PMID: 28991235 DOI: 10.1038/onc.2017.361]

10 **He J**, Xie Q, Xu H, Li J, Li Y. Circular RNAs and cancer. *Cancer Lett* 2017; **396**: 138-144 [PMID: 28342987 DOI: 10.1016/j.canlet.2017.03.027]

11 **Wang Y**, Mo Y, Gong Z, Yang X, Yang M, Zhang S, Xiong F, Xiang B, Zhou M, Liao Q, Zhang W, Li X, Li X, Li Y, Li G, Zeng Z, Xiong W. Circular RNAs in human cancer. *Mol Cancer* 2017; **16**: 25 [PMID: 28143578 DOI: 10.1186/s12943-017-0598-7]

12 **Zhou SY**, Chen W, Yang SJ, Li J, Zhang JY, Zhang HD, Zhong SL, Tang JH. Circular RNA circVAPA regulates breast cancer cell migration and invasion *via* sponging miR-130a-5p. *Epigenomics* 2020; **12**: 303-317 [PMID: 31920104 DOI: 10.2217/epi-2019-0124]

13 **Liu C**, Zhong X, Li J, Xu F. Circular RNA circVAPA Promotes Cell Proliferation in Hepatocellular Carcinoma. *Hum Gene Ther Clin Dev* 2019; **30**: 152-159 [PMID: 31368365 DOI: 10.1089/humc.2019.079]

14 **Esquela-Kerscher A**, Slack FJ. Oncomirs - microRNAs with a role in cancer. *Nat Rev Cancer* 2006; **6**: 259-269 [PMID: 16557279 DOI: 10.1038/nrc1840]

15 **Di Leva G**, Garofalo M, Croce CM. MicroRNAs in cancer. *Annu Rev Pathol* 2014; **9**: 287-314 [PMID: 24079833 DOI: 10.1146/annurev-pathol-012513-104715]

16 **Liu S**, Chen Q, Wang Y. MiR-125b-5p suppresses the bladder cancer progression *via* targeting HK2 and suppressing PI3K/AKT pathway. *Hum Cell* 2020; **33**: 185-194 [PMID: 31605287 DOI: 10.1007/s13577-019-00285-x]

17 **Hui L**, Zhang J, Guo X. MiR-125b-5p suppressed the glycolysis of laryngeal squamous cell carcinoma by down-regulating hexokinase-2. *Biomed Pharmacother* 2018; **103**: 1194-1201 [PMID: 29864898 DOI: 10.1016/j.biopha.2018.04.098]

18 **Shi H**, Li K, Feng J, Liu G, Feng Y, Zhang X. LncRNA-DANCR Interferes With miR-125b-5p/HK2 Axis to Desensitize Colon Cancer Cells to Cisplatin vis Activating Anaerobic Glycolysis. *Front Oncol* 2020; **10**: 1034 [PMID: 32766131 DOI: 10.3389/fonc.2020.01034]

19 **Yang W**, Ma J, Zhou W, Cao B, Zhou X, Yang Z, Zhang H, Zhao Q, Fan D, Hong L. Molecular mechanisms and theranostic potential of miRNAs in drug resistance of gastric cancer. *Expert Opin Ther Targets* 2017; **21**: 1063-1075 [PMID: 28994330 DOI: 10.1080/14728222.2017.1389900]

20 **Dehghanzadeh R**, Jadidi-Niaragh F, Gharibi T, Yousefi M. MicroRNA-induced drug resistance in gastric cancer. *Biomed Pharmacother* 2015; **74**: 191-199 [PMID: 26349984 DOI: 10.1016/j.biopha.2015.08.009]

21 **Wei L**, Sun J, Zhang N, Zheng Y, Wang X, Lv L, Liu J, Xu Y, Shen Y, Yang M. Noncoding RNAs in gastric cancer: implications for drug resistance. *Mol Cancer* 2020; **19**: 62 [PMID: 32192494 DOI: 10.1186/s12943-020-01185-7]

22 **Deng J**, Liu Y, Lee H, Herrmann A, Zhang W, Zhang C, Shen S, Priceman SJ, Kujawski M, Pal SK, Raubitschek A, Hoon DS, Forman S, Figlin RA, Liu J, Jove R, Yu H. S1PR1-STAT3 signaling is crucial for myeloid cell colonization at future metastatic sites. *Cancer Cell* 2012; **21**: 642-654 [PMID: 22624714 DOI: 10.1016/j.ccr.2012.03.039]

23 **Levy DE**, Lee CK. What does Stat3 do? *J Clin Invest* 2002; **109**: 1143-1148 [PMID: 11994402 DOI: 10.1172/JCI15650]

24 **Lee HJ**, Zhuang G, Cao Y, Du P, Kim HJ, Settleman J. Drug resistance *via* feedback activation of Stat3 in oncogene-addicted cancer cells. *Cancer Cell* 2014; **26**: 207-221 [PMID: 25065853 DOI: 10.1016/j.ccr.2014.05.019]

25 **Shan C**, Zhang Y, Hao X, Gao J, Chen X, Wang K. Biogenesis, functions and clinical significance of circRNAs in gastric cancer. *Mol Cancer* 2019; **18**: 136 [PMID: 31519189 DOI: 10.1186/s12943-019-1069-0]

26 **Liu YY**, Zhang LY, Du WZ. Circular RNA circ-PVT1 contributes to paclitaxel resistance of gastric cancer cells through the regulation of ZEB1 expression by sponging miR-124-3p. *Biosci Rep* 2019; **39** [PMID: 31793989 DOI: 10.1042/BSR20193045]

27 **Zhang Z**, Yu X, Zhou B, Zhang J, Chang J. Circular RNA circ\_0026359 Enhances Cisplatin Resistance in Gastric Cancer *via* Targeting miR-1200/POLD4 Pathway. *Biomed Res Int* 2020; **2020**: 5103272 [PMID: 32855967 DOI: 10.1155/2020/5103272]

28 **Huang X**, Li Z, Zhang Q, Wang W, Li B, Wang L, Xu Z, Zeng A, Zhang X, Zhang X, He Z, Li Q, Sun G, Wang S, Li Q, Wang L, Zhang L, Xu H, Xu Z. Circular RNA AKT3 upregulates PIK3R1 to enhance cisplatin resistance in gastric cancer *via* miR-198 suppression. *Mol Cancer* 2019; **18**: 71 [PMID: 30927924 DOI: 10.1186/s12943-019-0969-3]

29 **Huang XX**, Zhang Q, Hu H, Jin Y, Zeng AL, Xia YB, Xu L. A novel circular RNA circFN1 enhances cisplatin resistance in gastric cancer *via* sponging miR-182-5p. *J Cell Biochem* 2020 [PMID: 31898357 DOI: 10.1002/jcb.29641]

30 **Sun G**, Li Z, He Z, Wang W, Wang S, Zhang X, Cao J, Xu P, Wang H, Huang X, Xia Y, Lv J, Xuan Z, Jiang T, Fang L, Yang J, Zhang D, Xu H, Xu Z. Circular RNA MCTP2 inhibits cisplatin resistance in gastric cancer by miR-99a-5p-mediated induction of MTMR3 expression. *J Exp Clin Cancer Res* 2020; **39**: 246 [PMID: 33198772 DOI: 10.1186/s13046-020-01758-w]

31 **Li XN**, Wang ZJ, Ye CX, Zhao BC, Huang XX, Yang L. Circular RNA circVAPA is up-regulated and exerts oncogenic properties by sponging miR-101 in colorectal cancer. *Biomed Pharmacother* 2019; **112**: 108611 [PMID: 30797148 DOI: 10.1016/j.biopha.2019.108611]

32 **Gong X**, Xu B, Zi L, Chen X. miR-625 reverses multidrug resistance in gastric cancer cells by directly targeting ALDH1A1. *Cancer Manag Res* 2019; **11**: 6615-6624 [PMID: 31410057 DOI: 10.2147/CMAR.S208708]

33 **Chen J**, Zhou C, Li J, Xiang X, Zhang L, Deng J, Xiong J. miR‑21‑5p confers doxorubicin resistance in gastric cancer cells by targeting PTEN and TIMP3. *Int J Mol Med* 2018; **41**: 1855-1866 [PMID: 29393355 DOI: 10.3892/ijmm.2018.3405]

34 **Zhu QL**, Li Z, Lv CM, Wang W. MiR-187 influences cisplatin-resistance of gastric cancer cells through regulating the TGF-β/Smad signaling pathway. *Eur Rev Med Pharmacol Sci* 2019; **23**: 9907-9914 [PMID: 31799659 DOI: 10.26355/eurrev\_201911\_19556]

35 **Song S**, Min H, Niu M, Wang L, Wu Y, Zhang B, Chen X, Liang Q, Wen Y, Wang Y, Yi L, Wang H, Gao Q. S1PR1 predicts patient survival and promotes chemotherapy drug resistance in gastric cancer cells through STAT3 constitutive activation. *EBioMedicine* 2018; **37**: 168-176 [PMID: 30316864 DOI: 10.1016/j.ebiom.2018.10.005]

36 **Ma J**, Song X, Xu X, Mou Y. Cancer-Associated Fibroblasts Promote the Chemo-resistance in Gastric Cancer through Secreting IL-11 Targeting JAK/STAT3/Bcl2 Pathway. *Cancer Res Treat* 2019; **51**: 194-210 [PMID: 29690750 DOI: 10.4143/crt.2018.031]

37 **Huang S**, Chen M, Shen Y, Shen W, Guo H, Gao Q, Zou X. Inhibition of activated Stat3 reverses drug resistance to chemotherapeutic agents in gastric cancer cells. *Cancer Lett* 2012; **315**: 198-205 [PMID: 22104727 DOI: 10.1016/j.canlet.2011.10.011]

**Footnotes**

**Institutional review board statement:** This study was reviewed and approved by the First Affiliated Hospital of China Medical University.

**Institutional animal care and use committee statement:** The animal study was reviewed and approved by the First Affiliated Hospital of China Medical University.

**Conflict-of-interest statement:** The authors declare no conflict of interest related to this manuscript.

**Data sharing statement:** No additional data are available.

**ARRIVE guidelines statement:** The authors have read the ARRIVE guidelines, and the manuscript was prepared and revised according to the ARRIVE guidelines.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/

**Manuscript source:** Unsolicited manuscript

**Peer-review started:** December 6, 2020

**First decision:** December 17, 2020

**Article in press:**

**Specialty type:** Gastroenterology and hepatology

**Country/Territory of origin:** China

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): B


Grade C (Good): C, C

Grade D (Fair): 0


Grade E (Poor): 0

**P-Reviewer:** Mohamed SY, Ying G **S-Editor:** Fan JR **L-Editor:** Wang TQ **P-Editor:**


**Figure Legends**




**Figure 1 CircVAPA enhances proliferation and represses apoptosis of gastric cancer cells.** A: The expression of circVAPA was measured by qPCR in the gastric cancer tissues (*n* = 50) and adjacent normal tissues (*n* = 50); B-G: SGC7901 and HGC27 cells were treated with the circVAPA shRNA or control shRNA. Cell viability was tested by MTT assay (B and C), cell proliferation was measured by colony formation assay (D and E), and cell apoptosis was analyzed by flow cytometry (F and G). Data are presented as the mean ± SD. b*P* < 0.01.




**Figure 2 CircVAPA promotes invasion and migration of gastric cancer cells.** A-D: SGC7901 and HGC27 cells were treated with the circVAPA shRNA or control shRNA. Cell migration and invasion were tested by transwell assay (A and B), and migration and invasion were analyzed by wound healing assay (C and D). The wound healing proportion is shown. Data are presented as the mean ± SD. b*P* < 0.01.




**Figure 3 Elevation of CircVAPA enhances chemotherapy drug resistance of gastric cancer cells.** A: The expression of circVAPA, STAT3, Survivin, Mcl-1, and Bcl-xl was measured by qPCR in the SGC7901 and SGC7901/cisplatin (DDP) cells; B: STAT3 phosphorylation and levels of STAT3, Survivin, Mcl-1, and Bcl-xl were tested by Western blot analysis; C: SGC7901/DDP cells were initially treated with DDP at indicated doses and then with control shRNA or circVAPA shRNA. Cell viability was analyzed by MTT assay; D: SGC7901/DDP cells were treated with DDP or co-treated with DDP and circVAPA shRNA. Cell apoptosis was analyzed by flow cytometry. Data are presented as the mean ± SD. a*P* < 0.05.




**Figure 4 CircVAPA is able to sponge miR-125b-5p in gastric cancer cells.** A: The interaction of CircVAPA and miR-125b-5p was analyzed by bioinformatic analysis based on ENCORI (http://starbase.sysu.edu.cn/index.php); B-D: SGC7901 and HGC27 cells were treated with control mimic or miR-125b-5p mimic. The expression levels of miR-125b-5p were tested by qPCR in the cells (B), and luciferase activities of wild type CircVAPA and CircVAPA with the miR-125b-5p-binding site mutant were examined by luciferase reporter gene assay (C and D); E and F: SGC7901 and HGC27 cells were treated with the circVAPA shRNA or control shRNA. The expression of miR-125b-5p was analyzed by qPCR assay. Data are presented as the mean ± SD. b*P* < 0.01. MUT: Mutant; WT: Wild type.



**Figure 5 MiR-125b-5p targets STAT3 in gastric cancer cells.** A: The binding of miR-125b-5p and the 3’ untranslated region of *STAT3* was identified by bioinformatic analysis based on Targetscan (http://www.targetscan.org/vert\_72/); B-D: SGC7901 and HGC27 cells were treated with control mimic or miR-125b-5p mimic. The luciferase activities of wild type STAT3 and STAT3 with the miR-125b-5p-binding site mutant were examined by luciferase reporter gene assay (B), the mRNA expression of STAT3 was analyzed by qPCR assay (C), and the protein expression of STAT3 was determined by Western blot analysis (D); E: SGC7901 and HGC27 cells were treated with control shRNA or circVAPA shRNA, or co-treated with circVAPA shRNA and miR-125b-5p inhibitor. The protein expression of STAT3 was tested by Western blot analysis. Data are presented as the mean ± SD. b*P* < 0.01. MUT: Mutant; WT: Wild type.



**Figure 6 CircVAPA promotes chemotherapy drug resistance of gastric cancer cells by modulating miR-125b-5p/STAT3 axis.** A and B: SGC7901 and HGC27 cells were treated with cisplatin (DDP), DDP, and circVAPA shRNA, or co-treated with DDP, circVAPA shRNA, and miR-125b-5p inhibitor. Cell viability was measured by MTT assay; C: SGC7901/DDP cells were treated with DDP or co-treated with DDP and pcDNA3.1-circVAPA at the indicated dose, or co-treated with DDP, pcDNA3.1-circVAPA, and STAT3 siRNA. Cell viability was measured by MTT assay; D and E: SGC7901 and HGC27 cells were treated with DDP, DDP, and circVAPA shRNA, or co-treated with DDP, circVAPA shRNA, and miR-125b-5p inhibitor or pcDNA3.1-STAT3. Cell apoptosis was analyzed by flow cytometry. Data are presented as the mean ± SD. b*P* < 0.01. DDP: Cisplatin.



**Figure 7 CircVAPA promotes tumor growth of chemoresistant gastric cancer cells *in vivo*.** A-D: The impact of circVAPA on tumor growth of melanoma cells *in vivo* was analyzed by nude mice tumorigenicity assay (*n* = 5). SGC7901/cisplatin cells were treated with control shRNA or circVAPA shRNA. Representative images of dissected tumors from nude mice are shown (A). The average tumor volume (B) and weight (C) were calculated and presented. The expression of miR-125b-5p was measured by qPCR in the tumor tissues of the mice (D); E: The expression of STAT3 was tested by Western blot analysis in the tumor tissues of the mice. Data are presented as the mean ± SD. b*P* < 0.01.